ArticleClinical cancer research : an official journal of the American Association for Cancer Research2009
Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancer.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- A systematic review of serum autoantibodies as biomarkers for pancreatic cancer detection.Oncotarget · 2016Pooled it
- Novel perspectives on MSLN-targeted cancer therapy: from molecular mechanisms to clinical translation.Cancer biology & therapy · 2025Review
- Advancing Immunotherapy in Pancreatic Cancer: A Brief Review of Emerging Adoptive Cell Therapies.Cancers · 2025Review
- Recent Developments in Nanotechnology and Immunotherapy for the Diagnosis and Treatment of Pancreatic Cancer.Current pharmaceutical biotechnology · 2025Review
- High mesothelin expression is associated with low cytotoxic T cell infiltration in pancreatic cancer.Frontiers in immunology · 2025Article
- MSLN induced EMT, cancer stem cell traits and chemotherapy resistance of pancreatic cancer cells.Heliyon · 2024Article
- Biology of Mesothelin and Clinical Implications: A Review of Existing Literature.World journal of oncology · 2023Review
- Multianalyte Serum Biomarker Panel for Early Detection of Pancreatic Adenocarcinoma.JCO clinical cancer informatics · 2023Article
- Biomarkers in the diagnosis of pancreatic cancer: Are we closer to finding the golden ticket?World journal of gastroenterology · 2021Review
- Defining Immunogenic and Radioimmunogenic Tumors.Frontiers in oncology · 2021Review
- Inhibition of Cholesterol Esterification Enzyme Enhances the Potency of Human Chimeric Antigen Receptor T Cells against Pancreatic Carcinoma.Molecular therapy oncolytics · 2020Article
- Article
- Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities.Gastroenterology · 2019Review
- Glycoprotein biomarkers for the detection of pancreatic ductal adenocarcinoma.World journal of gastroenterology · 2018Review
- The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review.Targeted oncology · 2018Review
- Prediction of improved survival in patients with pancreatic cancer via IL-21 enhanced detection of mesothelin epitope-reactive T-cell responses.Oncotarget · 2018Article
- Mesothelin as a novel biomarker and immunotherapeutic target in human glioblastoma.Oncotarget · 2017Article
- Postoperative Adjuvant Therapy for Resectable Pancreatic Cancer With Gemcitabine and Adoptive Immunotherapy.Pancreas · 2017Article
- Current status of biomarker and targeted nanoparticle development: The precision oncology approach for pancreatic cancer therapy.Cancer letters · 2017Article
- Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?Oncoimmunology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
Abstract
purposeMesothelin is a glycoprotein expressed on normal mesothelial cells and is overexpressed in several histologic types of tumors including pancreatic adenocarcinomas. A soluble form of mesothelin has been detected in patients with ovarian cancer and malignant mesothelioma, and has prognostic value. Mesothelin has also been considered as a target for immune-based therapies. We conducted a study on the potential clinical utility of mesothelin as a biomarker for pancreatic disease and therapeutic target pancreatic cancer. EXPERIMENTAL
designTumor cell-bound and soluble mesothelin in patients was evaluated by immunohistochemistry and ELISA, respectively. The in vitro cellular immune response to mesothelin was evaluated by INF gamma ELISA and intracellular cytokine staining for IFN gamma in CD4(+) and CD8(+) T cells. The level of circulating antibodies to mesothelin was measured by ELISA.
resultsAll tumor tissue from patients with pancreatic adenocarcinoma expressed mesothelin (n = 10). Circulating mesothelin protein was detected in patients with pancreatic adenocarcinoma (73 of 74 patients) and benign pancreatic disease (5 of 5) but not in healthy individuals. Mesothelin-specific CD4(+) and CD8(+) T cells were generated from peripheral blood lymphocytes of patients with pancreatic cancer in 50% of patients compared with only 20% of healthy individuals. Antibodies reactive to mesothelin were detected in <3% of either patients or healthy individuals.
conclusionsCirculating mesothelin is a useful biomarker for pancreatic disease. Furthermore, mesothelin-specific T cells can be induced in patients with pancreatic cancer. This suggests that mesothelin is a potential target for immune-based intervention strategies in pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.